Publications by authors named "Matthew D Snape"

Claim this Profile
S
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.
Sabine Schnyder Ghamloush, Sue Fanning, Brandon Essink, Frank Eder, Matthew D Snape

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
Anette-Gabriele Ziegler, Peter Achenbach, Andreas Weiß, Reinhard Berner, Kristina Casteels, Matthew D Snape

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Ali Amini, Lucy C Garner, Robert H Shaw, Neil Wrigley Kelly, Sandra Adele, Matthew D Snape

Sci Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
Dima El Safadi, Lisa Hitchins, Ashleigh Howard, Parvinder Aley, Jaclyn Bowman, Matthew D Snape

J Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemic.
Ivo Zeller, Andreas Weiss, Stefanie Arnolds, Katharina Schütte-Borkovec, Sari Arabi, Matthew D Snape

Infection· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal influenza vaccines (ComFluCOV).
Rajeka Lazarus, Rosie Harris, Russell Thirard, Sarah Baos, Lucy Culliford, Matthew D Snape

Vaccine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, phase IV randomised controlled trial of two schedules of a four-component meningococcal B vaccine in UK preterm infants.
Anna Calvert, Nick Andrews, Sheula Barlow, Ray Borrow, Charlotte Black, Matthew D Snape

Arch Dis Child· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Alexander Maytum, David Porter, Philip de Whalley, Amber Thompson, Emma Plested, Matthew D Snape

Pediatr Infect Dis J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children.
Sabine Schnyder Ghamloush, Brandon Essink, Bo Hu, Shiva Kalidindi, Louie Morsy, Matthew D Snape

Pediatrics· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus.
Gu-Lung Lin, Simon B Drysdale, Matthew D Snape, Daniel O'Connor, Anthony Brown

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Helen Ratcliffe, Karen S Tiley, Stephanie Longet, Claire Tonry, Cathal Roarty, Matthew D Snape

iScience· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Eimear Kelly, Melanie Greenland, Philip C S de Whalley, Parvinder K Aley, Emma L Plested, Matthew D Snape

J Infect· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Xinxue Liu, Alasdair P S Munro, Annie Wright, Shuo Feng, Leila Janani, Matthew D Snape

J Infect· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children.
Dmitri Kazmin, Elizabeth A Clutterbuck, Giorgio Napolitani, Amanda L Wilkins, Andrea Tarlton, Matthew D Snape

NPJ Vaccines· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Robert H Shaw, Melanie Greenland, Arabella S V Stuart, Parvinder K Aley, Nick J Andrews, Matthew D Snape

J Infect· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
David Goldblatt, Nick J Andrews, Carmen L Sheppard, Samuel Rose, Parvinder K Aley, Matthew D Snape

Vaccine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Xinxue Liu, Alasdair Ps Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Matthew D Snape

J Infect· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial.
Anna Calvert, Gayatri Amirthalingam, Nick Andrews, Sneha Basude, Matthew Coleman, Matthew D Snape

Lancet Microbe· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.
Joanne G Wildenbeest, Marie-Noëlle Billard, Roy P Zuurbier, Koos Korsten, Annefleur C Langedijk, Matthew D Snape

Lancet Respir Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.
Zhuxin Mao, Xiao Li, Ana Dacosta-Urbieta, Marie-Noëlle Billard, Joanne Wildenbeest, Matthew D Snape

Vaccine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K Aley, Sandra Belij-Rammerstorfer, Matthew D Snape

Clin Exp Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Matthew Rajan, Natalie Marchevsky, Gemma Sinclair, Katie O'Brien, Kimberley Jefferies, Matthew D Snape

Pediatr Infect Dis J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
Arabella S V Stuart, Miia Virta, Kristi Williams, Ilkka Seppa, Robyn Hartvickson, Matthew D Snape

J Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-containing vaccines or received no pertussis-containing vaccine in pregnancy in England.
Shari Sapuan, Nick Andrews, Bassam Hallis, Laura Hole, Christine E Jones, Matthew D Snape

Vaccine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiating vaccine reactions from invasive bacterial infections in young infants presenting to the emergency department in the 4CMenB era: a retrospective observational comparison.
Samuel William Channon-Wells, Emily Tough, Neda So, Daniel O'Connor, Matthew D Snape

BMJ Paediatr Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis